Novus Therapeutics, Inc. announced that on September 9, 2020, David-Alexandre C. Gros, M.D. was appointed as the Chief Executive Officer. Gros replaces Jon Ku wahara as the Company’s principal executive officer following Kuwahara’s appointment as the Company’s interim principal executive officer on September 4, 2020. Kuwahara continues to serve as Novus’s principal financial officer and principal accounting officer. Gros had been serving as an advisor to Novus since May 2020 and joined Novus from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where since May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Since November 2018, he has also served on the board of directors of Eliem Pharmaceuticals. He previously served as President and Chief Operating Officer of Neurocrine Biosciences, Inc., from January to December 2017.